4519 Share Price Performance
JP¥0
-7387.00 (-100.00%)
Price JP¥0
Fair ValueJP¥8,571.43
Share Pricen/a
Chugai Pharmaceutical Co., Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
4519 Community Narratives
AN
Fair Value JP¥8.57k 8.3% overvalued intrinsic discount
Roche Collaboration And Biologics Pipeline Will Expand Healthcare Reach
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value JP¥6.58k 41.0% overvalued intrinsic discount
Global Pricing Cuts And Pipeline Delays Will Dim Prospects
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value JP¥10.73k 13.5% undervalued intrinsic discount
Aging Populations And Precision Medicine Will Expand Biologics Access
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Global Pricing Cuts And Pipeline Delays Will Dim Prospects
Key Takeaways Reliance on a narrow set of high-earning drugs and pipeline uncertainty increases exposure to competitive threats and potential revenue volatility. Ongoing price pressures, biosimilar competition, and major capital investments risk squeezing margins, straining cash flow, and impacting long-term growth prospects.Read more
26
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
JP¥6.58k
41.0% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
2.77% p.a.
Profit Margin
36.19%
Future PE
25.26x
Price in 2029
JP¥7.58k
Roche Collaboration And Biologics Pipeline Will Expand Healthcare Reach
Key Takeaways Focus on biologics, personalized medicine, and R&D productivity positions Chugai well for future growth and expansion of high-value therapies. Strategic partnerships, supply chain investments, and innovation improve global reach, production efficiency, and profit potential.Read more
84
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
JP¥8.57k
8.3% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
7.36% p.a.
Profit Margin
38.78%
Future PE
27.89x
Price in 2028
JP¥9.87k
Aging Populations And Precision Medicine Will Expand Biologics Access
Key Takeaways Robust drug pipeline management and advanced manufacturing scale position Chugai to outpace rivals in innovation, output, and profitability as global biologic demand rises. Strategic investments in AI-driven discovery and portfolio focus enhance R&D productivity, enabling strong market leadership in next-generation, high-margin therapies.Read more
21
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
JP¥10.73k
13.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
10.05% p.a.
Profit Margin
40.79%
Future PE
31.18x
Price in 2028
JP¥12.32k
Trending Discussion
Recently Updated Narratives
AN
4519: Rising Dividends And Rich P/E Will Likely Limit Future Upside
Fair Value: JP¥6.58k 41.0% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
4519: Merger And Renal Portfolio Expansion Will Shape Balanced Outlook In 2025
Fair Value: JP¥8.57k 8.3% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Precision Medicine Will Expand Biologics Access
Fair Value: JP¥10.73k 13.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Chugai Pharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 24, 2026
- 263.72
- 71.09%
- 34.50%
- 0%
About 4519
- Founded
- 1925
- Employees
- 5026
- CEO
- WebsiteView website
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.